Kiran Mazumdar-Shaw is an Indian billionaire entrepreneur. She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, a biotechnology company based in Bangalore, India and the former chairperson of Indian Institute of Management, Bangalore.
A pioneer of the biotechnology industry in India and the head
of the country’s leading biotechnology enterprise, Biocon, Ms.
Kiran Mazumdar-Shaw is a highly respected businesswoman.
Ms. Mazumdar-Shaw, a first generation entrepreneur, has made
her country proud with a globally recognized biopharmaceutical
enterprise that is committed to innovation and affordability in
delivering world-class therapeutics to patients globally.
A successful technocrat of global standing, Ms Kiran Mazumdar-Shaw heads India’s leading
biopharmaceutical enterprise, Biocon. She is highly respected in the corporate world and has been
named among TIME magazine’s ‘100 Most Influential People in the World.’ She has also featured
in Fierce Biotech’s list of ‘World’s 25 Most Influential People in Biopharma’ and is recognized
among Forbes ‘100 Most Powerful Women’ globally. U.S.-based Chemical Heritage Foundation
recently conferred Ms Mazumdar-Shaw with the ‘2014 Othmer Gold Medal’ and Germany-based
Kiel Institute for the World Economy awarded her its coveted ‘2014 Global Economy Prize’ for
Business. Her most cherished awards are the national awards, PADMA SHRI (1989) and PADMA
BHUSHAN (2005), presented to her by the President of India for her pioneering efforts in
Under her stewardship, Biocon has evolved from its inception in 1978 as an industrial enzymes
company to a fully integrated innovation-led Biopharmaceutical enterprise committed to reduce
therapy costs of chronic diseases like autoimmune, diabetes and cancer. As an emerging global
biopharmaceutical enterprise, serving customers in over 85 countries through innovative products
and research services, it is enabling access to affordable healthcare for patients, partners and
healthcare systems across the globe. It has successfully developed and taken a range of novel
biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin
and analogs from ‘Lab to Market’. It has a rich pipeline of biosimilars and novel biologics at
various stages of development, including a high potential oral insulin..
Ms Mazumdar-Shaw’s commitment to affordable healthcare extends beyond business. She is
passionately focused on innovation-led healthcare solutions for sustainable and affordable health-
care for the marginalized communities. Her philanthropic initiatives include an innovative micro-
health insurance program based on delivering cashless healthcare through primary healthcare
clinics in rural areas of Karnataka, an education initiative based on math education for school
children in government schools as well as making quality cancer care affordable to a larger patient
population. She has established the 1,400-bed Mazumdar-Shaw Cancer Center (MSCC) in
Bangalore in partnership with renowned heart surgeon Dr Devi Shetty to deliver affordable world-
class cancer care services to patients irrespective of socio-economic status.
More recently she has also established the Mazumdar Shaw Center for Translational Research
(MSCTR), a non-profit research institute dedicated to developing scientific breakthroughs
resulting in more effective treatments for a wide range of human diseases and conditions. Ms
Mazumdar-Shaw is also focusing on ensuring access to affordable healthcare for the marginalized
communities through telemedicine initiatives like eLaaj, preventive screenings for oral and
cervical cancer etc.
Biocon Limited is an Indian biopharmaceutical company that is based in Bangalore, India founded by Kiran Mazumdar-Shaw. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon’s biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In contract research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon.